Amedisys (NASDAQ: AMED) reported Q3 EPS of $0.34, $0.01 better than the analyst estimate of $0.33. Revenue for the quarter came in at $326.44 million versus the consensus estimate of $312.22 million.

Paul B. Kusserow, President and Chief Executive Officer stated, “We are encouraged by the company’s continued strong performance in the third quarter. Both segments achieved significant revenue growth and we have continued to make investments that will position us well to capitalize on future opportunities supporting our long-term strategic vision. I would like to thank our dedicated employees for their unwavering commitment to the patients we serve.”

For earnings history and earnings-related data on Amedisys (AMED) click here.